|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cancer Genome Atlas Network, .
Comprehensive molecular characterization of human colon and rectal
cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kloor M and von Knebel Doeberitz M: The
immune biology of microsatellite-unstable cancer. Trends Cancer.
2:121–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koopman M, Kortman GA, Mekenkamp L,
Ligtenberg MJ, Hoogerbrugge N, Antonini NF, Punt CJ and van Krieken
JH: Deficient mismatch repair system in patients with sporadic
advanced colorectal cancer. Br J Cancer. 100:266–273. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sargent DJ, Marsoni S, Monges G, Thibodeau
SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri
V, et al: Defective mismatch repair as a predictive marker for lack
of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
J Clin Oncol. 28:3219–3226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Escudier B, Motzer RJ, Sharma P, Wagstaff
J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski
PG, et al: Treatment beyond progression in patients with advanced
renal cell carcinoma treated with nivolumab in CheckMate 025. Eur
Urol. 72:368–376. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bauer K, Nelius N, Reuschenbach M, Koch M,
Weitz J, Steinert G, Kopitz J, Beckhove P, Tariverdian M, von
Knebel Doeberitz M and Kloor M: T cell responses against
microsatellite instability-induced frameshift peptides and
influence of regulatory T cells in colorectal cancer. Cancer
Immunol Immunother. 62:27–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dudley JC, Lin MT, Le DT and Eshleman JR:
Microsatellite instability as a biomarker for PD-1 blockade. Clin
Cancer Res. 22:813–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Y, Sethi NS, Hinoue T, Schneider BG,
Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R,
Islam M, et al: Comparative molecular analysis of gastrointestinal
adenocarcinomas. Cancer Cell. 33:721–735.e8. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wallin JJ, Bendell JC, Funke R, Sznol M,
Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, et al:
Atezolizumab in combination with bevacizumab enhances
antigen-specific T-cell migration in metastatic renal cell
carcinoma. Nat Commun. 7:126242016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ayers M, Lunceford J, Nebozhyn M, Murphy
E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran
V, et al: IFN-γ-related mRNA profile predicts clinical response to
PD-1 blockade. J Clin Invest. 127:2930–2940. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakayama Y, Mimura K, Tamaki T, Shiraishi
K, Kua LF, Koh V, Ohmori M, Kimura A, Inoue S, Okayama H, et al:
Phospho-STAT1 expression as a potential biomarker for
anti-PD-1/anti-PD-L1 immunotherapy for breast cancer. Int J Oncol.
54:2030–2038. 2019.PubMed/NCBI
|
|
23
|
Ashizawa M, Okayama H, Ishigame T, Thar
Min AK, Saito K, Ujiie D, Murakami Y, Kikuchi T, Nakayama Y, Noda
M, et al: miRNA-148a-3p regulates immunosuppression in DNA mismatch
repair-deficient colorectal cancer by targeting PD-L1. Mol Cancer
Res. 17:1403–1413. 2019.PubMed/NCBI
|
|
24
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Noda M, Okayama H, Tachibana K, Sakamoto
W, Saito K, Thar Min AK, Ashizawa M, Nakajima T, Aoto K, Momma T,
et al: Glycosyltransferase gene expression identifies a poor
prognostic colorectal cancer subtype associated with mismatch
repair deficiency and incomplete glycan synthesis. Clin Cancer Res.
24:4468–4481. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khodarev NN, Roizman B and Weichselbaum
RR: Molecular pathways: Interferon/stat1 pathway: Role in the tumor
resistance to genotoxic stress and aggressive growth. Clin Cancer
Res. 18:3015–3021. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McGranahan N, Furness AJ, Rosenthal R,
Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak
NJ, Hiley CT, et al: Clonal neoantigens elicit T cell
immunoreactivity and sensitivity to immune checkpoint blockade.
Science. 351:1463–1469. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Postow MA, Callahan MK and Wolchok JD:
Immune checkpoint blockade in cancer therapy. J Clin Oncol.
33:1974–1982. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McLaughlin J, Han G, Schalper KA,
Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R,
LoRusso P and Rimm DL: Quantitative assessment of the heterogeneity
of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol.
2:46–54. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bhaijee F and Anders RA: PD-L1 expression
as a predictive biomarker: Is absence of proof the same as proof of
absence? JAMA Oncol. 2:54–55. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schalper KA, Kaftan E and Herbst RS:
Predictive biomarkers for PD-1 axis therapies: The hidden treasure
or a call for research. Clin Cancer Res. 22:2102–2104. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nishino M, Ramaiya NH, Hatabu H and Hodi
FS: Monitoring immune-checkpoint blockade: Response evaluation and
biomarker development. Nat Rev Clin Oncol. 14:655–668. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gibney GT, Weiner LM and Atkins MB:
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Lancet Oncol. 17:e542–e551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mimura K, Kua LF, Shiraishi K, Kee Siang
L, Shabbir A, Komachi M, Suzuki Y, Nakano T, Yong WP, So J and Kono
K: Inhibition of mitogen-activated protein kinase pathway can
induce upregulation of human leukocyte antigen class I without
PD-L1-upregulation in contrast to interferon-gamma treatment.
Cancer Sci. 105:1236–1244. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mimura K, Teh JL, Okayama H, Shiraishi K,
Kua LF, Koh V, Smoot DT, Ashktorab H, Oike T, Suzuki Y, et al:
PD-L1 expression is mainly regulated by interferon gamma associated
with JAK-STAT pathway in gastric cancer. Cancer Sci. 109:43–53.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
De Smedt L, Lemahieu J, Palmans S, Govaere
O, Tousseyn T, Van Cutsem E, Prenen H, Tejpar S, Spaepen M,
Matthijs G, et al: Microsatellite instable vs. stable colon
carcinomas: Analysis of tumour heterogeneity, inflammation and
angiogenesis. Br J Cancer. 113:500–509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Boissière-Michot F, Lazennec G, Frugier H,
Jarlier M, Roca L, Duffour J, Du Paty E, Laune D, Blanchard F, Le
Pessot F, et al: Characterization of an adaptive immune response in
microsatellite-instable colorectal cancer. Oncoimmunology.
3:e292562014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pagès F, Mlecnik B, Marliot F, Bindea G,
Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al:
International validation of the consensus Immunoscore for the
classification of colon cancer: A prognostic and accuracy study.
Lancet. 391:2128–2139. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Le Gouvello S, Bastuji-Garin S, Aloulou N,
Mansour H, Chaumette MT, Berrehar F, Seikour A, Charachon A, Karoui
M, Leroy K, et al: High prevalence of Foxp3 and IL17 in
MMR-proficient colorectal carcinomas. Gut. 57:772–779. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Michel S, Benner A, Tariverdian M,
Wentzensen N, Hoefler P, Pommerencke T, Grabe N, von Knebel
Doeberitz M and Kloor M: High density of FOXP3-positive T cells
infiltrating colorectal cancers with microsatellite instability. Br
J Cancer. 99:1867–1873. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Salama P, Phillips M, Grieu F, Morris M,
Zeps N, Joseph D, Platell C and Iacopetta B: Tumor-infiltrating
FOXP3+ T regulatory cells show strong prognostic significance in
colorectal cancer. J Clin Oncol. 27:186–192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Blatner NR, Bonertz A, Beckhove P, Cheon
EC, Krantz SB, Strouch M, Weitz J, Koch M, Halverson AL, Bentrem DJ
and Khazaie K: In colorectal cancer mast cells contribute to
systemic regulatory T-cell dysfunction. Proc Natl Acad Sci USA.
107:6430–6435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Frey DM, Droeser RA, Viehl CT, Zlobec I,
Lugli A, Zingg U, Oertli D, Kettelhack C, Terracciano L and
Tornillo L: High frequency of tumor-infiltrating FOXP3(+)
regulatory T cells predicts improved survival in mismatch
repair-proficient colorectal cancer patients. Int J Cancer.
126:2635–2643. 2010.PubMed/NCBI
|
|
44
|
Clarke SL, Betts GJ, Plant A, Wright KL,
El-Shanawany TM, Harrop R, Torkington J, Rees BI, Williams GT,
Gallimore AM and Godkin AJ: CD4+CD25+FOXP3+ regulatory T cells
suppress anti-tumor immune responses in patients with colorectal
cancer. PLoS One. 1:e1292006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Loddenkemper C, Schernus M, Noutsias M,
Stein H, Thiel E and Nagorsen D: In situ analysis of FOXP3+
regulatory T cells in human colorectal cancer. J Transl Med.
4:522006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ling KL, Pratap SE, Bates GJ, Singh B,
Mortensen NJ, George BD, Warren BF, Piris J, Roncador G, Fox SB, et
al: Increased frequency of regulatory T cells in peripheral blood
and tumour infiltrating lymphocytes in colorectal cancer patients.
Cancer Immun. 7:72007.PubMed/NCBI
|
|
47
|
Masugi Y, Nishihara R, Yang J, Mima K, da
Silva A, Shi Y, Inamura K, Cao Y, Song M, Nowak JA, et al: Tumour
CD274 (PD-L1) expression and T cells in colorectal cancer. Gut.
66:1463–1473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liston A and Gray DH: Homeostatic control
of regulatory T cell diversity. Nat Rev Immunol. 14:154–165. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fabrizio DA, George TJ Jr, Dunne RF,
Frampton G, Sun J, Gowen K, Kennedy M, Greenbowe J, Schrock AB,
Hezel AF, et al: Beyond microsatellite testing: Assessment of tumor
mutational burden identifies subsets of colorectal cancer who may
respond to immune checkpoint inhibition. J Gastrointest Oncol.
9:610–617. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang Z, Duan J, Cai S, Han M, Dong H, Zhao
J, Zhu B, Wang S, Zhuo M, Sun J, et al: Assessment of blood tumor
mutational burden as a potential biomarker for immunotherapy in
patients with non-small cell lung cancer with use of a
next-generation sequencing cancer gene panel. JAMA Oncol.
5:696–702. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chan TA, Yarchoan M, Jaffee E, Swanton C,
Quezada SA, Stenzinger A and Peters S: Development of tumor
mutation burden as an immunotherapy biomarker: Utility for the
oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cohen R, Hain E, Buhard O, Guilloux A,
Bardier A, Kaci R, Bertheau P, Renaud F, Bibeau F, Fléjou JF, et
al: Association of primary resistance to immune checkpoint
inhibitors in metastatic colorectal cancer with misdiagnosis of
microsatellite instability or mismatch repair deficiency status.
JAMA Oncol. 5:551–555. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang C, Gong J, Tu TY, Lee PP and Fakih M:
Immune profiling of microsatellite instability-high and polymerase
epsilon (POLE)-mutated metastatic colorectal tumors identifies
predictors of response to anti-PD-1 therapy. J Gastrointest Oncol.
9:404–415. 2018. View Article : Google Scholar : PubMed/NCBI
|
